German Public Health Insurance Posts €2.6 Billion Surplus in First Half of 2026, But Underlying Deficit Persists as Hospital Costs Surge 9.3 Percent

FDA Clears AstraZeneca's Etcamah for a Genetically Defined Subset of First-Line Breast Cancer | iPharmaCenter

Ionis Wins First Ever FDA Approval for an Alexander Disease Treatment, Marking a Turning Point for a Disease With No Prior Options

International Myeloma Society Annual Meeting | 2026

European Commission | EMA Drug Approvals | 2026 | iPharmaCenter

Pharmaceutical Healthcare Deals & Acquisitions - 2026 | iPharmaCenter

European Society of Cardiology (ESC) Congress 2026 | News | Updates | iPharmaCenter

INDIAN HEALTHCARE SYSTEM | HEALTHCARE SYSTEM OF INDIA | NEWS | BLOGS | IPHARMACENTER

FDA Approves Takeda’s MIMRYLO for Polycythemia Vera | iPharmaCenter

FDA Approves Revolution Medicines’ RASONQUE for Metastatic Pancreatic Cancer | iPharmaCenter

China: NMPA Approves New Therapies | 2026

FDA Approves Johnson and Johnson’s IMAAVY for Warm Autoimmune Hemolytic Anemia | iPharmaCenter

Japan Approves GSK’s Hibsago for Chronic Hepatitis B and Takeda’s Orzeyful for Narcolepsy Type 1

MHLW Japan | CHUIKYO Drug Price calculations | iPharmaCenter

NICE Assessment Outcomes | 2026

Regeneron's Pasatru wins FDA nod as second FOP therapy, first to cut flare-ups and new bone lesions

Moderna Merck Collaboration News | iPharmaCenter

South Korea Healthcare and Pharma News: Policy, and Market Access

NICE Backs Donidalorsen for Hereditary Angioedema and Acalabrutinib for Blood Cancers

FDA Clears Ultragenyx Gene Therapy for Glycogen Storage Disease Type Ia

AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC

Top 10 Immunology Drugs by 2026 Revenue: Dupixent, Skyrizi and Rinvoq Lead

Best-Selling Cancer Drugs 2025: Top 10 by Revenue

Employers Look to PBMs for Lower Drug Costs and Better Access | iPharmaCenter

Saudi SFDA Launches NADR Program to Accelerate Rare Disease Drug Access

Saudi Arabia Grants World’s First Approval for Iberdomide in Multiple Myeloma | iPharmaCenter

FDA Grants Accelerated Approval to Zenbexus Combination for Relapsed Multiple Myeloma | iPharmaCenter

Top 10 pharmaceutical companies by revenues in 2026 | Official Figures | iPharmaCenter

Top 10 Pharma Companies by Revenue in 2025 | iPharmaCenter

Italy | AIFA | Healthcare Updates | iPharmaCenter

ANVISA Updates: Breakthrough Oncology and Pediatric Approvals in Brazil | JUly 2026

Italy’s Medicine Spending Reaches €39.3 Billion in 2025 | iPharmaCenter

NICE Backs Acalabrutinib for Mantle Cell Lymphoma and Untreated CLL

Top 10 U.S. healthcare companies by 2026 revenue | iPharmaCenter

FDA clears Pluvicto earlier in PSMA positive metastatic prostate cancer

EU Approves Datroway as 1L Monotherapy in PD‑1/PD‑L1–Ineligible Metastatic TNBC After TROPION‑Breast02 Survival Gain

UK greenlights aficamten: thousands with obstructive HCM gain faster access to once-daily therapy

UnitedHealth Scales Tennessee Health Hubs with $4M to Reach 200,000 Residents by 2027

European Commission Authorizes RINVOQ for Severe Alopecia Areata

AstraZeneca's trastuzumab deruxtecan approved by CDSCO for adults with HER2-positive Stage II or III early breast cancer | iPharmaCenter

Johnson & Johnson Expands Oncology and Immunology Pipelines via Multi-Billion-Dollar Deals | iPharmaCenter

FDA Approves Otsuka’s SIMTRIYO as First-in-Class NDSRI for ADHD

Sanofi Terminates Amlitelimab Development in Atopic Dermatitis | iPharmaCenter

Takeda Secures Landmark Approval for Orzeyful in China | iPharmaCenter

FDA Approves Jideytro for Previously Treated ROS1 Positive Non Small Cell Lung Cancer

India's CDSCO Grants Regulatory Approval for Takeda’s Qdenga Dengue Vaccine

CMS Outlines Operational Path for 2028 Maximum Fair Price Compliance

CMS Targets Fee-for-Service Fragmentation in New 2027 Policy Roadmap

Alzheimer’s Association International Conference (AAIC) 2026 | iPharmaCenter

FDA Approves First Oral PCSK9 Inhibitor, Signaling Shift in Dyslipidemia Treatment